Skip to main content
. 2013 Feb 14;108(4):771–774. doi: 10.1038/bjc.2013.41

Figure 2.

Figure 2

Kaplan–Meier curves of progression-free survival (A) and overall survival (B) for advanced oesophagogastric cancer patients treated with weekly docetaxel plus cetuximab (n=38).